Go to the profile of Icell Kealex Therapeutics

Icell Kealex Therapeutics

  • 346-772-0323
  • Networkers
  • United States of America

About Icell Kealex Therapeutics

Icell Kealex Therapeutics is an oncology biotech startup based at JLABS at the Texas Medical Center in Houston, Texas. We are developing oncoloytic vaccinia viruses armed with T-cell-engaging antibody fragments that boost the virus’s antitumor efficacy. This modification in the virus allows the tumor cells that are not infected with the virus to be target by T-cells. Icell Kealex has a deep pipeline of T cell engager oncolytic vaccinia virus which offer an advantage over other oncolytic viruses. We plan to enter phase 1 trials with our lead product in 2018. We are looking for co-development or licensing partnerships

Therapeutic Areas



Regenerative medicine

Company Type

Biotechnology – Diagnostics

State of Ownership


Influencer Of


Topics contributed to:


Editions participated in:

March 2017